vTv Therapeutics Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for vTv Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" vTv Therapeutics stock.
View analyst ratings for vTv Therapeutics or view top-rated stocks.

Wall Street analysts have given vTv Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but vTv Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

vTv Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for vTv Therapeutics.

vTv Therapeutics Inc. (NASDAQ:VTVT) released its earnings results on Wednesday, February, 24th. The biotechnology company reported $0.02 EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.08. The biotechnology company had revenue of $6.40 million for the quarter, compared to the consensus estimate of $3.30 million.
View vTv Therapeutics' earnings history.

vTv Therapeutics' stock was trading at $2.43 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, VTVT stock has increased by 11.5% and is now trading at $2.71.
View which stocks have been most impacted by COVID-19.

1 brokerages have issued 12 month price objectives for vTv Therapeutics' shares. Their forecasts range from $8.00 to $8.00. On average, they anticipate vTv Therapeutics' share price to reach $8.00 in the next year. This suggests a possible upside of 195.2% from the stock's current price.
View analysts' price targets for vTv Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to vTv Therapeutics include Vectura Group (VEGPF), BioXcel Therapeutics (BTAI), Merus (MRUS), Ardelyx (ARDX), Affimed (AFMD), ESSA Pharma (EPIX), Epizyme (EPZM), ADVANZ PHARMA (CXRXF), Amphastar Pharmaceuticals (AMPH), Collegium Pharmaceutical (COLL), Humanigen (HGEN), ORIC Pharmaceuticals (ORIC), Esperion Therapeutics (ESPR), Lexicon Pharmaceuticals (LXRX) and Karyopharm Therapeutics (KPTI).
View all of VTVT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other vTv Therapeutics investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), (CGC), Onconova Therapeutics (ONTX), Vaxart (VXRT), Agile Therapeutics (AGRX) and Idera Pharmaceuticals (IDRA).

(VTVT) raised $125 million in an initial public offering (IPO) on Thursday, July 30th 2015. The company issued 7,800,000 shares at $15.00-$17.00 per share. Piper Jaffray and Stifel served as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.

vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."

Shares of VTVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VTVT stock can currently be purchased for approximately $2.71.

vTv Therapeutics has a market capitalization of $218.60 million and generates $2.76 million in revenue each year. The biotechnology company earns $-13,040,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis.

vTv Therapeutics employs 25 workers across the globe.

The official website for vTv Therapeutics is www.vtvtherapeutics.com.

vTv Therapeutics is headquartered at 3980 PREMIER DR SUITE 310, HIGH POINT NC, 27265.

vTv Therapeutics' mailing address is 3980 PREMIER DR SUITE 310, HIGH POINT NC, 27265. The biotechnology company can be reached via phone at 336-841-0300 or via email at [email protected]